Alphamab Oncology Presents New Progress in Clinical Research of JSKN003

June 3, 2025  Source: drugdu 72

"/June 3, Alphamab Oncology Pharmaceuticals (09966) announced that it recently presented the latest research results of JSKN003 at the 2025 ASCO Annual Meeting. The study conducted a summary analysis of the efficacy and safety of multiple indications, mainly including a Phase I clinical study in patients with advanced/metastatic solid tumors, involving different doses of JSKN003.

As of February 28, 2025, a total of 46 PROC patients participated in the study. Among them, 91.3% of patients had tumor shrinkage, the objective response rate (ORR) was 63.0%, the median progression-free survival (mPFS) was 7.7 months, and the 9-month overall survival rate (OS) was 89.9%. In HER2 IHC 0 patients, the ORR was 52.4%, and in HER2 IHC 1+, 2+, and 3+ patients, the ORR was 72.2%. In terms of safety, 19.6% of patients experienced grade 3 or 4 treatment-related adverse events (TRAEs), but no deaths caused by TRAEs occurred.

In addition, the announcement also mentioned the performance of JSKN003 in patients with HER2-positive breast cancer who had previously undergone multiple lines of treatment. A total of 88 patients participated, with a confirmed ORR of 54.7% and a median duration of remission (DoR) of 18.4 months. In terms of safety, 15.9% of patients experienced grade 3 or above TRAEs, and no TRAEs led to death. Studies have shown that JSKN003 has shown effectiveness in different HER2 expression subgroups, and multiple Phase III clinical trials are ongoing.

https://finance.eastmoney.com/a/202506033420356814.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.